The DOI matches its Crossref record; 567 of the 567 references it cites were found in a registry or an index.
Antithrombotic Therapy for Atrial Fibrillation
Open accessAbstract
BACKGROUND: The risk of stroke is heterogeneous across different groups of patients with atrial fibrillation (AF), being dependent on the presence of various stroke risk factors. We provide recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at varying levels of stroke risk and in a number of common clinical scenarios. METHODS: Systematic literature reviews were conducted to identify relevant articles published from the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines (9th Edition). The overall quality of the evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach. Graded recommendations and ungraded consensus‐based statements were drafted, voted on, and revised until consensus was reached. RESULTS: For patients with AF without valvular heart disease, including those with paroxysmal AF, who are at low risk of stroke (eg, CHA2DS2‐VASc [congestive heart failure, hypertension, age ≥ 75 (doubled), diabetes, stroke (doubled)‐vascular disease, age 65‐74 and sex category (female)] score of 0 in males or 1 in females), we suggest no antithrombotic therapy. The next step is to consider stroke prevention (ie, oral anticoagulation therapy) for patients with 1 or more non‐sex CHA2DS2‐VASc stroke risk factors. For patients with a single non‐sex CHA2DS2‐VASc stroke risk factor, we suggest oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel; and for those at high risk of stroke (eg, CHA2DS2‐VASc ≥ 2 in males or ≥ 3 in females), we recommend oral anticoagulation rather than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we recommend or suggest in favor of oral anticoagulation, we suggest using a non‐vitamin K antagonist oral anticoagulant drug rather than adjusted‐dose vitamin K antagonist therapy. With the latter, it is important to aim for good quality anticoagulation control with a time in therapeutic range > 70%. Attention to modifiable bleeding risk factors (eg, uncontrolled BP, labile international normalized ratios, concomitant use of aspirin or nonsteroidal antiinflammatory drugs in an anticoagulated patient, alcohol excess) should be made at each patient contact, and HAS‐BLED (hypertension, abnormal renal/liver function [1 point each], stroke, bleeding history or predisposition, labile international normalized ratio, elderly (0.65), drugs/alcohol concomitantly [1 point each]) score used to assess the risk of bleeding where high risk patients (≥ 3) should be reviewed and followed up more frequently. CONCLUSIONS: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with AF with ≥1 non‐sex CHA2DS2‐VASc stroke risk factor(s).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citationKearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Ruff, C. T., Giugliano, R. P., Braunwald, E., Hoffman, E. B., Deenadayalu, N., Ezekowitz, M. D., Camm, A. J., Weitz, J. I., Lewis, B. S., Parkhomenko, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62343-0 · Cited by 5,051 · cited 2×
“A meta-analysis of the four phase 3 trials compared patients taking NOACs (higher dose) (n 1⁄4 42,411) with warfarin (n 1⁄4 29,272) (e-Table 15).(124) NOACs significantly reduced stroke or systemic embolic events by 19% compared with warfarin (RR, 0.”
BackgroundSCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Pisters, R., Lane, D. A., Nieuwlaat, R., de Vos, C. B., Crijns, H. J. G. M., & Lip, G. Y. H. (2010) · Chest · doi:10.1378/chest.10-0134 · Cited by 4,505
Self-citation2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy
Authors/Task Force members, Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., Hagege, A. A., Lafont, A., Limongelli, G., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu284 · Cited by 4,332
(2008) · Cited by 3,790
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Iakovou, I. (2005) · JAMA · doi:10.1001/jama.293.17.2126 · Cited by 3,132
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Chapter 9: Analysing Data and Undertaking Meta-Analyses
Deeks, J. J., Higgins, J. P. T., & Altman, D. G. (2008) · Cited by 2,782
Calkins, H., Kuck, K. H., Cappato, R., Brugada, J., Camm, A. J., Chen, S.-A., Crijns, H. J. G., Damiano, R. J., Davies, D. W., DiMarco, J., et al. (2012) · Europace · doi:10.1093/europace/eus027 · Cited by 2,722
Self-citationMiyasaka, Y., Barnes, M. E., Gersh, B. J., Cha, S. S., Bailey, K. R., Abhayaratna, W. P., Seward, J. B., & Tsang, T. S. M. (2006) · Circulation · doi:10.1161/circulationaha.105.595140 · Cited by 2,564
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“The Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial compared apixaban 5 mg bid with aspirin in AF patients who were not candidates for VKA therapy.(125) The trial was stopped early for ben…”
Holmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., Mullin, C. M., & Sick, P. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61343-x · Cited by 2,240
Cryptogenic stroke and underlying atrial fibrillation
Sanna, T., Diener, H.-C., Passman, R. S., Di Lazzaro, V., Bernstein, R. A., Morillo, C. A., Rymer, M. M., Thijs, V., Rogers, T., Beckers, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313600 · Cited by 2,161
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Subclinical atrial fibrillation and the risk of stroke
Healey, J. S., Connolly, S. J., Gold, M. R., Israel, C. W., Van Gelder, I. C., Capucci, A., Lau, C. P., Fain, E., Yang, S., Bailleul, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105575 · Cited by 2,100
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study
Lloyd-Jones, D. M., Wang, T. J., Leip, E. P., Larson, M. G., Levy, D., Vasan, R. S., D’Agostino, R. B., Massaro, J. M., Beiser, A., Wolf, P. A., et al. (2004) · Circulation · doi:10.1161/01.cir.0000140263.20897.42 · Cited by 2,041
ESC Guidelines on the management of cardiovascular diseases during pregnancy
Endorsed by the European Society of Gynecology (ESG), T. A. F. E. P. C. (., Authors/Task Force Members, Regitz-Zagrosek, V., Blomstrom Lundqvist, C., Borghi, C., Cifkova, R., Ferreira, R., Foidart, J.-M., Gibbs, J. S. R., Gohlke-Baerwolf, C., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr218 · Cited by 1,924
Self-citationSummary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Holmes, D. R., Kar, S., Price, M. J., Whisenant, B., Sievert, H., Doshi, S. K., Huber, K., & Reddy, V. Y. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.04.029 · Cited by 1,845
Petersen, P., Godtfredsen, J., Boysen, G., Andersen, E., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,820
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
Chimowitz, M. I., Lynn, M. J., Howlett-Smith, H., Stern, B. J., Hertzberg, V. S., Frankel, M. R., Levine, S. R., Chaturvedi, S., Kasner, S. E., Benesch, C. G., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043033 · Cited by 1,744
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Dewilde, W. J., Oirbans, T., Verheugt, F. W., Kelder, J. C., De Smet, B. J., Herrman, J.-P., Adriaenssens, T., Vrolix, M., Heestermans, A. A., Vis, M. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62177-1 · Cited by 1,719
Stroke Prevention in Atrial Fibrillation Study. Final results.
(1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation
Blackshear, J. L., & Odell, J. A. (1996) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(95)00887-x · Cited by 1,686 · cited 1×
“Occlusion of the LAA With Devices or Surgical Techniques: Approximately 90% of the thrombi found in patients with non-valvular AF and 57% of the thrombi found in valvular AF are located in the LAA.(445)”
MethodEmbolic strokes of undetermined source: the case for a new clinical construct
Hart, R. G., Diener, H.-C., Coutts, S. B., Easton, J. D., Granger, C. B., O'Donnell, M. J., Sacco, R. L., & Connolly, S. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70310-7 · Cited by 1,681
Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,638
Prevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590
Self-citationMant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
(1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,530
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy
Bates, S. M., Greer, I. A., Middeldorp, S., Veenstra, D. L., Prabulos, A.-M., & Vandvik, P. O. (2012) · Chest · doi:10.1378/chest.11-2300 · Cited by 1,525
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506 · cited 1×
“org and more bleeding.(440) However, patients with bioprosthetic valves were included in the ARISTOTLE trial(441) (apixban), theEffectiveAnticoagulationwith Factor XaNext Generation inAtrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) trial(442) (edoxaban), and the relative efficacy…”
ResultAgeno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Olesen, J. B., Lip, G. Y. H., Hansen, M. L., Hansen, P. R., Tolstrup, J. S., Lindhardsen, J., Selmer, C., Ahlehoff, O., Olsen, A.-M. S., Gislason, G. H., et al. (2011) · BMJ · doi:10.1136/bmj.d124 · Cited by 1,428
Self-citationAndrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416
Stroke Severity in Atrial Fibrillation: The Framingham Study
Lin, H.-J., Wolf, P. A., Kelly-Hayes, M., Beiser, A. S., Kase, C. S., Benjamin, E. J., & D'Agostino, R. B. (1996) · Stroke · doi:10.1161/01.str.27.10.1760 · Cited by 1,389
Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383
Self-citationStangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Atrial fibrillation in patients with cryptogenic stroke
Gladstone, D. J., Spring, M., Dorian, P., Panzov, V., Thorpe, K. E., Hall, J., Vaid, H., O'Donnell, M., Laupacis, A., Côté, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311376 · Cited by 1,276
Evidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Chen, Z.-M. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04010-5 · Cited by 1,232
Friberg, L., Rosenqvist, M., & Lip, G. Y. H. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr488 · Cited by 1,192
Self-citationPerioperative Bridging Anticoagulation in Patients with Atrial Fibrillation
Douketis, J. D., Spyropoulos, A. C., Kaatz, S., Becker, R. C., Caprini, J. A., Dunn, A. S., Garcia, D. A., Jacobson, A., Jaffer, A. K., Kong, D. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501035 · Cited by 1,184 · cited 2×
“The role of bridging has been tested in a randomized trial, Bridging Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE), performed in patients on warfarin who were candidates for an invasive procedure (patients with mechanical valve…”
BackgroundMethodWilber, D. J., Pappone, C., Neuzil, P., De Paola, A., Marchlinski, F., Natale, A., Macle, L., Daoud, E. G., Calkins, H., Hall, B., et al. (2010) · JAMA · doi:10.1001/jama.2009.2029 · Cited by 1,170
Calkins, H., Hindricks, G., Cappato, R., Kim, Y.-H., Saad, E. B., Aguinaga, L., Akar, J. G., Badhwar, V., Brugada, J., Camm, J., et al. (2018) · EP Europace · doi:10.1093/europace/eux274 · Cited by 1,164
Self-citationIdarucizumab for Dabigatran Reversal — Full Cohort Analysis
Pollack, C. V., Reilly, P. A., van Ryn, J., Eikelboom, J. W., Glund, S., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kam, C.-W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707278 · Cited by 1,154
Wazni, O. M., Marrouche, N. F., Martin, D. O., Verma, A., Bhargava, M., Saliba, W., Bash, D., Schweikert, R., Brachmann, J., Gunther, J., et al. (2005) · JAMA · doi:10.1001/jama.293.21.2634 · Cited by 1,121
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
Canadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,111
Lip, G. Y. H., Frison, L., Halperin, J. L., & Lane, D. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.024 · Cited by 1,080
Self-citationWarfarin in the Prevention of Stroke Associated with Nonrheumatic Atrial Fibrillation
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301143280227 · Cited by 1,067
Reddy, V. Y., Sievert, H., Halperin, J., Doshi, S. K., Buchbinder, M., Neuzil, P., Huber, K., Whisenant, B., Kar, S., Swarup, V., et al. (2014) · JAMA · doi:10.1001/jama.2014.15192 · Cited by 1,018
Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria
Knudsen, K. A., Rosand, J., Karluk, D., & Greenberg, S. M. (2001) · Neurology · doi:10.1212/wnl.56.4.537 · Cited by 1,015
Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61194-4 · Cited by 1,013
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008
Circumferential Pulmonary-Vein Ablation for Chronic Atrial Fibrillation
Oral, H., Pappone, C., Chugh, A., Good, E., Bogun, F., Pelosi, F., Bates, E. R., Lehmann, M. H., Vicedomini, G., Augello, G., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa050955 · Cited by 976
Use of Transesophageal Echocardiography to Guide Cardioversion in Patients with Atrial Fibrillation
Klein, A. L., Grimm, R. A., Murray, R. D., Apperson-Hansen, C., Asinger, R. W., Black, I. W., Davidoff, R., Erbel, R., Halperin, J. L., Orsinelli, D. A., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441901 · Cited by 951
Lipowski, Z. J. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92478-7 · Cited by 944
Stroke and bleeding in atrial fibrillation with chronic kidney disease
Olesen, J. B., Lip, G. Y. H., Kamper, A.-L., Hommel, K., Køber, L., Lane, D. A., Lindhardsen, J., Gislason, G. H., & Torp-Pedersen, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105594 · Cited by 930
Self-citationRisk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin
Hylek, E. M., & Singer, D. E. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-11-199406010-00001 · Cited by 919
Antithrombotic Therapy for Atrial Fibrillation
You, J. J., Singer, D. E., Howard, P. A., Lane, D. A., Eckman, M. H., Fang, M. C., Hylek, E. M., Schulman, S., Go, A. S., Hughes, M., et al. (2012) · Chest · doi:10.1378/chest.11-2304 · Cited by 918
Self-citationCatheter Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation: The A4 Study
Jaïs, P., Cauchemez, B., Macle, L., Daoud, E., Khairy, P., Subbiah, R., Hocini, M., Extramiana, F., Sacher, F., Bordachar, P., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.772582 · Cited by 891
Glotzer, T. V., Daoud, E. G., Wyse, D. G., Singer, D. E., Ezekowitz, M. D., Hilker, C., Miller, C., Qi, D., & Ziegler, P. D. (2009) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.109.849638 · Cited by 879 · cited 1×
“8% per year).(383) Integration of AHRE presence, duration, or burden ($ 5min or$ 24 h) into risk scores for thromboembolism”
BackgroundConnolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation · doi:10.1161/circulationaha.107.750000 · Cited by 870
Odutayo, A., Wong, C. X., Hsiao, A. J., Hopewell, S., Altman, D. G., & Emdin, C. A. (2016) · BMJ · doi:10.1136/bmj.i4482 · Cited by 867
Reddy, V. Y., Holmes, D., Doshi, S. K., Neuzil, P., & Kar, S. (2011) · Circulation · doi:10.1161/circulationaha.110.976449 · Cited by 863
Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., et al. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.271 · Cited by 855
A New Risk Scheme to Predict Warfarin-Associated Hemorrhage
Fang, M. C., Go, A. S., Chang, Y., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Singer, D. E. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.03.031 · Cited by 852
Atrial fibrillation management: a prospective survey in ESC Member Countries
Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S., Breithardt, G., Le Heuzey, J.-Y., Prins, M. H., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi505 · Cited by 829
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 807
Hylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350802 · Cited by 789
Wang, T. J., Massaro, J. M., Levy, D., Vasan, R. S., Wolf, P. A., D'Agostino, R. B., Larson, M. G., Kannel, W. B., & Benjamin, E. J. (2003) · JAMA · doi:10.1001/jama.290.8.1049 · Cited by 780
Landefeld, C. S., & Goldman, L. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90564-0 · Cited by 778
Beyth, R. J., Quinn, L. M., & Landefeld, C. S. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00198-3 · Cited by 773
Glotzer, T. V., Hellkamp, A. S., Zimmerman, J., Sweeney, M. O., Yee, R., Marinchak, R., Cook, J., Paraschos, A., Love, J., Radoslovich, G., et al. (2003) · Circulation · doi:10.1161/01.cir.0000057981.70380.45 · Cited by 750
Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
Angiographic Follow-up after Placement of a Self-Expanding Coronary-Artery Stent
Serruys, P. W., Strauss, B. H., Beatt, K. J., Bertrand, M. E., Puel, J., Rickards, A. F., Meier, B., Goy, J.-J., Vogt, P., Kappenberger, L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101033240103 · Cited by 732
van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B. (2002) · JAMA · doi:10.1001/jama.288.19.2441 · Cited by 714
Go, A. S., Hylek, E. M., Chang, Y., Phillips, K. A., Henault, L. E., Capra, A. M., Jensvold, N. G., Selby, J. V., & Singer, D. E. (2003) · JAMA · doi:10.1001/jama.290.20.2685 · Cited by 703
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 701
Sposato, L. A., Cipriano, L. E., Saposnik, G., Vargas, E. R., Riccio, P. M., & Hachinski, V. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70027-x · Cited by 694
Pappone, C., Augello, G., Sala, S., Gugliotta, F., Vicedomini, G., Gulletta, S., Paglino, G., Mazzone, P., Sora, N., Greiss, I., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.037 · Cited by 686
Reddy, V. Y., Doshi, S. K., Sievert, H., Buchbinder, M., Neuzil, P., Huber, K., Halperin, J. L., & Holmes, D. (2013) · Circulation · doi:10.1161/circulationaha.112.114389 · Cited by 677
Temporal relationship between subclinical atrial fibrillation and embolic events
Brambatti, M., Connolly, S. J., Gold, M. R., Morillo, C. A., Capucci, A., Muto, C., Lau, C. P., Van Gelder, I. C., Hohnloser, S. H., Carlson, M., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.007825 · Cited by 676
Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy
Hart, R. G., Pearce, L. A., Rothbart, R. M., McAnulty, J. H., Asinger, R. W., & Halperin, J. L. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00489-1 · Cited by 663
Shen, A. Y.-J., Yao, J. F., Brar, S. S., Jorgensen, M. B., & Chen, W. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.098 · Cited by 656
The Net Clinical Benefit of Warfarin Anticoagulation in Atrial Fibrillation
Singer, D. E., Chang, Y., Fang, M. C., Borowsky, L. H., Pomernacki, N. K., Udaltsova, N., & Go, A. S. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-5-200909010-00003 · Cited by 656
Stangier, J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847050-00001 · Cited by 655
Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis
Poon, M. T. C., Fonville, A. F., & Al-Shahi Salman, R. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306476 · Cited by 653
Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation: – The J-ROCKET AF Study –
Hori, M., Matsumoto, M., Tanahashi, N., Momomura, S.-I., Uchiyama, S., Goto, S., Izumi, T., Koretsune, Y., Kajikawa, M., Kato, M., et al. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0454 · Cited by 641
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
Page, R. L., Wilkinson, W. E., Clair, W. K., McCarthy, E. A., & Pritchett, E. L. (1994) · Circulation · doi:10.1161/01.cir.89.1.224 · Cited by 627 · cited 1×
“episodes of AF recurrence, with 1 series suggesting that only 1 in every 12 paroxysms are symptomatic.(263)”
BackgroundThe ABC pathway: an integrated approach to improve AF management
Lip, G. Y. H. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.153 · Cited by 627
Self-citationAntithrombotic and Thrombolytic Therapy for Valvular Disease
Whitlock, R. P., Sun, J. C., Fremes, S. E., Rubens, F. D., & Teoh, K. H. (2012) · Chest · doi:10.1378/chest.11-2305 · Cited by 625
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT
Van Gelder, I. C., Healey, J. S., Crijns, H. J. G. M., Wang, J., Hohnloser, S. H., Gold, M. R., Capucci, A., Lau, C.-P., Morillo, C. A., Hobbelt, A. H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx042 · Cited by 599
National trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Roubin, G. S., Cannon, A. D., Agrawal, S. K., Macander, P. J., Dean, L. S., Baxley, W. A., & Breland, J. (1992) · Circulation · doi:10.1161/01.cir.85.3.916 · Cited by 582
Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Jaeschke, R., Guyatt, G. H., Dellinger, P., Schunemann, H., Levy, M. M., Kunz, R., Norris, S., Bion, J., & for the GRADE working group (2008) · BMJ · doi:10.1136/bmj.a744 · Cited by 577
Characteristics and Prognosis of Lone Atrial Fibrillation: 30-Year Follow-up in the Framingham Study
Brand, F. N. (1985) · JAMA · doi:10.1001/jama.1985.03360240061035 · Cited by 577
White, H. D. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.3.239 · Cited by 575
Hohnloser, S. H., Hijazi, Z., Thomas, L., Alexander, J. H., Amerena, J., Hanna, M., Keltai, M., Lanas, F., Lopes, R. D., Lopez-Sendon, J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs274 · Cited by 574
Task Force Members, Lip, G. Y. H., Windecker, S., Huber, K., Kirchhof, P., Marin, F., Ten Berg, J. M., Haeusler, K. G., Boriani, G., Capodanno, D., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu298 · Cited by 566
Self-citationA specific antidote for dabigatran: functional and structural characterization
Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., & Litzenburger, T. (2013) · Blood · doi:10.1182/blood-2012-11-468207 · Cited by 563
Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update
Hart, R. G., Catanese, L., Perera, K. S., Ntaios, G., & Connolly, S. J. (2017) · Stroke · doi:10.1161/strokeaha.116.016414 · Cited by 553
Hemorrhagic and Ischemic Strokes Compared: Stroke Severity, Mortality, and Risk Factors
Andersen, K. K., Olsen, T. S., Dehlendorff, C., & Kammersgaard, L. P. (2009) · Stroke · doi:10.1161/strokeaha.108.540112 · Cited by 552
Zabalgoitia, M., Halperin, J. L., Pearce, L. A., Blackshear, J. L., Asinger, R. W., & Hart, R. G. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00146-6 · Cited by 550
Bonati, L. H., Dobson, J., Featherstone, R. L., Ederle, J., van der Worp, H. B., de Borst, G. J., Mali, W. P. T. M., Beard, J. D., Cleveland, T., Engelter, S. T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61184-3 · Cited by 550
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., & Manning, W. J. (2004) · Chest · doi:10.1378/chest.126.3_suppl.429s · Cited by 547
Success of Surgical Left Atrial Appendage Closure
Kanderian, A. S., Gillinov, A. M., Pettersson, G. B., Blackstone, E., & Klein, A. L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.067 · Cited by 545
Holmes, D. R., Doshi, S. K., Kar, S., Price, M. J., Sanchez, J. M., Sievert, H., Valderrabano, M., & Reddy, V. Y. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.04.025 · Cited by 543
(1997) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)83303-x · Cited by 539
Man-Son-Hing, M., Nichol, G., Lau, A., & Laupacis, A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.7.677 · Cited by 538
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors
van der Meer, F. J. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.13.1557 · Cited by 538
Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration
Freedman, B., Camm, J., Calkins, H., Healey, J. S., Rosenqvist, M., Wang, J., Albert, C. M., Anderson, C. S., Antoniou, S., Benjamin, E. J., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.026693 · Cited by 537
Self-citationHart, R. G., Pearce, L. A., McBride, R., Rothbart, R. M., & Asinger, R. W. (1999) · Stroke · doi:10.1161/01.str.30.6.1223 · Cited by 533
Fang, M. C., Chang, Y., Hylek, E. M., Rosand, J., Greenberg, S. M., Go, A. S., & Singer, D. E. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00005 · Cited by 532
Stoddard, M. F., Dawkins, P. R., Prince, C. R., & Ammash, N. M. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)00396-8 · Cited by 532
Nagarakanti, R., Ezekowitz, M. D., Oldgren, J., Yang, S., Chernick, M., Aikens, T. H., Flaker, G., Brugada, J., Kamenský, G., Parekh, A., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.977546 · Cited by 526
Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514
Paciaroni, M., Agnelli, G., Corea, F., Ageno, W., Alberti, A., Lanari, A., Caso, V., Micheli, S., Bertolani, L., Venti, M., et al. (2008) · Stroke · doi:10.1161/strokeaha.107.510321 · Cited by 507
Stabile, G., Bertaglia, E., Senatore, G., De Simone, A., Zoppo, F., Donnici, G., Turco, P., Pascotto, P., Fazzari, M., & Vitale, D. F. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi583 · Cited by 503
Healey, J. S., Crystal, E., Lamy, A., Teoh, K., Semelhago, L., Hohnloser, S. H., Cybulsky, I., Abouzahr, L., Sawchuck, C., Carroll, S., et al. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.09.054 · Cited by 496
Lip, G. Y. H., Frison, L., Halperin, J. L., & Lane, D. A. (2010) · Stroke · doi:10.1161/strokeaha.110.590257 · Cited by 491
Self-citationHijazi, Z., Oldgren, J., Lindbäck, J., Alexander, J. H., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Held, C., Hylek, E. M., Lopes, R. D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00741-8 · Cited by 490
Effect of Study Setting on Anticoagulation Control
van Walraven, C., Jennings, A., Oake, N., Fergusson, D., & Forster, A. J. (2006) · Chest · doi:10.1378/chest.129.5.1155 · Cited by 487
Di Biase, L., Burkhardt, J. D., Santangeli, P., Mohanty, P., Sanchez, J. E., Horton, R., Gallinghouse, G. J., Themistoclakis, S., Rossillo, A., Lakkireddy, D., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.006426 · Cited by 485
Dans, A. L., Connolly, S. J., Wallentin, L., Yang, S., Nakamya, J., Brueckmann, M., Ezekowitz, M., Oldgren, J., Eikelboom, J. W., Reilly, P. A., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.115386 · Cited by 484
Apostolakis, S., Sullivan, R. M., Olshansky, B., & Lip, G. Y. H. (2013) · Chest · doi:10.1378/chest.13-0054 · Cited by 482
Self-citationPrimary and Secondary Prevention of Cardiovascular Disease
Vandvik, P. O., Lincoff, A. M., Gore, J. M., Gutterman, D. D., Sonnenberg, F. A., Alonso-Coello, P., Akl, E. A., Lansberg, M. G., Guyatt, G. H., & Spencer, F. A. (2012) · Chest · doi:10.1378/chest.11-2306 · Cited by 476
Fang, M. C., Singer, D. E., Chang, Y., Hylek, E. M., Henault, L. E., Jensvold, N. G., & Go, A. S. (2005) · Circulation · doi:10.1161/circulationaha.105.553438 · Cited by 469
Stroke prevention in atrial fibrillation
Freedman, B., Potpara, T. S., & Lip, G. Y. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31257-0 · Cited by 463
Self-citationHohnloser, S. H., Pajitnev, D., Pogue, J., Healey, J. S., Pfeffer, M. A., Yusuf, S., & Connolly, S. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.076 · Cited by 460
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke
Lansberg, M. G., O'Donnell, M. J., Khatri, P., Lang, E. S., Nguyen-Huynh, M. N., Schwartz, N. E., Sonnenberg, F. A., Schulman, S., Vandvik, P. O., Spencer, F. A., et al. (2012) · Chest · doi:10.1378/chest.11-2302 · Cited by 455
Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes
Dukkipati, S. R., Kar, S., Holmes, D. R., Doshi, S. K., Swarup, V., Gibson, D. N., Maini, B., Gordon, N. T., Main, M. L., & Reddy, V. Y. (2018) · Circulation · doi:10.1161/circulationaha.118.035090 · Cited by 451
Ostermayer, S. H., Reisman, M., Kramer, P. H., Matthews, R. V., Gray, W. A., Block, P. C., Omran, H., Bartorelli, A. L., Della Bella, P., Di Mario, C., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.042 · Cited by 444
Fiedler, K. A., Maeng, M., Mehilli, J., Schulz-Schüpke, S., Byrne, R. A., Sibbing, D., Hoppmann, P., Schneider, S., Fusaro, M., Ott, I., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.050 · Cited by 443
Larsen, T. B., Skjøth, F., Nielsen, P. B., Kjældgaard, J. N., & Lip, G. Y. H. (2016) · BMJ · doi:10.1136/bmj.i3189 · Cited by 441
Self-citationThe ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
O'Brien, E. C., Simon, D. N., Thomas, L. E., Hylek, E. M., Gersh, B. J., Ansell, J. E., Kowey, P. R., Mahaffey, K. W., Chang, P., Fonarow, G. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv476 · Cited by 440
Boersma, L. V., Ince, H., Kische, S., Pokushalov, E., Schmitz, T., Schmidt, B., Gori, T., Meincke, F., Protopopov, A. V., Betts, T., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.05.038 · Cited by 433
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
Calkins, H., Willems, S., Gerstenfeld, E. P., Verma, A., Schilling, R., Hohnloser, S. H., Okumura, K., Serota, H., Nordaby, M., Guiver, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701005 · Cited by 430
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
Self-citationBoriani, G., Glotzer, T. V., Santini, M., West, T. M., De Melis, M., Sepsi, M., Gasparini, M., Lewalter, T., Camm, J. A., & Singer, D. E. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht491 · Cited by 427
Self-citationPark, J., Bethencourt, A., Sievert, H., Santoro, G., Meier, B., Walsh, K., Lopez‐Minquez, J. R., Meerkin, D., Valdés, M., Ormerod, O., et al. (2011) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.22764 · Cited by 423
Cappato, R., Marchlinski, F. E., Hohnloser, S. H., Naccarelli, G. V., Xiang, J., Wilber, D. J., Ma, C.-S., Hess, S., Wells, D. S., Juang, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv177 · Cited by 422
Berge, E., Abdelnoor, M., Nakstad, P., & Sandset, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02085-7 · Cited by 421
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0172 · Cited by 414
Kirchhof, P., Ammentorp, B., Darius, H., De Caterina, R., Le Heuzey, J.-Y., Schilling, R. J., Schmitt, J., & Zamorano, J. L. (2014) · EP Europace · doi:10.1093/europace/eut263 · Cited by 404
Capucci, A., Santini, M., Padeletti, L., Gulizia, M., Botto, G., Boriani, G., Ricci, R., Favale, S., Zolezzi, F., Di Belardino, N., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.07.044 · Cited by 401
Self-citationLip, G. Y. H., Freedman, B., De Caterina, R., & Potpara, T. S. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-11-0876 · Cited by 400
Self-citationArnold, A. Z., Mick, M. J., Mazurek, R. P., Loop, F. D., & Trohman, R. G. (1992) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(92)90530-z · Cited by 392
Ganesan, A. N., Chew, D. P., Hartshorne, T., Selvanayagam, J. B., Aylward, P. E., Sanders, P., & McGavigan, A. D. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw007 · Cited by 391
Baudo, F., Collins, P., Huth-Kühne, A., Lévesque, H., Marco, P., Nemes, L., Pellegrini, F., Tengborn, L., & Knoebl, P. (2012) · Blood · doi:10.1182/blood-2012-02-408930 · Cited by 386
BOTTO, G. L., PADELETTI, L., SANTINI, M., CAPUCCI, A., GULIZIA, M., ZOLEZZI, F., FAVALE, S., MOLON, G., RICCI, R., BIFFI, M., et al. (2009) · Journal of Cardiovascular Electrophysiology · doi:10.1111/j.1540-8167.2008.01320.x · Cited by 380
Self-citationThe Global Burden of Atrial Fibrillation and Stroke
Lip, G. Y. H., Brechin, C. M., & Lane, D. A. (2012) · Chest · doi:10.1378/chest.11-2888 · Cited by 379
Self-citationIncidence and predictors of atrial flutter in the general population
Granada, J., Uribe, W., Chyou, P.-H., Maassen, K., Vierkant, R., Smith, P. N., Hayes, J., Eaker, E., & Vidaillet, H. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00982-7 · Cited by 375
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
Cappato, R., Ezekowitz, M. D., Klein, A. L., Camm, A. J., Ma, C.-S., Le Heuzey, J.-Y., Talajic, M., Scanavacca, M., Vardas, P. E., Kirchhof, P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu367 · Cited by 372
Hughes, M., Lip, G. Y. H., & on behalf of the Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-08-0508 · Cited by 371
Self-citationManning, W. J., Leeman, D. E., Gotch, P. J., & Come, P. C. (1989) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(89)90602-5 · Cited by 371
Prognostic implications of left artial spontaneous echo contrast in nonvalvular atrial fibrillation
Leung, D. Y. C., Black, I. W., Cranney, G. B., Hopkins, A. P., & Walsh, W. F. (1994) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(94)90025-6 · Cited by 365
Oldgren, J., Healey, J. S., Ezekowitz, M., Commerford, P., Avezum, A., Pais, P., Zhu, J., Jansky, P., Sigamani, A., Morillo, C. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005451 · Cited by 365
Husted, S., Wallentin, L., Andreotti, F., Arnesen, H., Bachmann, F., Baigent, C., Huber, K., Jespersen, J., Kristensen, S., Lip, G. Y. H., et al. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-06-0403 · Cited by 364
Self-citationApostolakis, S., Lane, D. A., Guo, Y., Buller, H., & Lip, G. Y. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.06.019 · Cited by 358
Self-citationPerioperative atrial fibrillation and the long-term risk of ischemic stroke
Gialdini, G., Nearing, K., Bhave, P. D., Bonuccelli, U., Iadecola, C., Healey, J. S., & Kamel, H. (2014) · JAMA · doi:10.1001/jama.2014.9143 · Cited by 355
Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation
Fauchier, L., Cinaud, A., Brigadeau, F., Lepillier, A., Pierre, B., Abbey, S., Fatemi, M., Franceschi, F., Guedeney, P., Jacon, P., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.076 · Cited by 352
Flaker, G. C., Belew, K., Beckman, K., Vidaillet, H., Kron, J., Safford, R., Mickel, M., & Barrell, P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2004.06.032 · Cited by 341 · cited 1×
“In addition, the high prevalence of asymptomatic AF makes determining the exact duration of AF difficult.(266)”
BackgroundLamberts, M., Gislason, G. H., Olesen, J. B., Kristensen, S. L., Schjerning Olsen, A.-M., Mikkelsen, A., Christensen, C. B., Lip, G. Y. H., Køber, L., Torp-Pedersen, C., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.029 · Cited by 334
Self-citationRothberg, M. B., Celestin, C., Fiore, L. D., Lawler, E., & Cook, J. R. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-4-200508160-00005 · Cited by 334
Liao, J., Khalid, Z., Scallan, C., Morillo, C., & O’Donnell, M. (2007) · Stroke · doi:10.1161/strokeaha.106.478685 · Cited by 331
Manning, W. J., Silverman, D. I., Gordon, S., Krumholz, H. M., & Douglas, P. S. (1993) · New England Journal of Medicine · doi:10.1056/nejm199303183281102 · Cited by 330
Daoud, E. G., Glotzer, T. V., Wyse, D. G., Ezekowitz, M. D., Hilker, C., Koehler, J., & Ziegler, P. D. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.04.022 · Cited by 326
Lip, G. Y. H., Laroche, C., Dan, G.-A., Santini, M., Kalarus, Z., Rasmussen, L. H., Oliveira, M. M., Mairesse, G., Crijns, H. J. G. M., Simantirakis, E., et al. (2014) · EP Europace · doi:10.1093/europace/eut373 · Cited by 322
Self-citationMelgaard, L., Gorst-Rasmussen, A., Lane, D. A., Rasmussen, L. H., Larsen, T. B., & Lip, G. Y. H. (2015) · JAMA · doi:10.1001/jama.2015.10725 · Cited by 315
Self-citationLovelock, C., Molyneux, A., & Rothwell, P. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70107-2 · Cited by 313
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Self-citationAttia, Z. I., Noseworthy, P. A., Lopez-Jimenez, F., Asirvatham, S. J., Deshmukh, A. J., Gersh, B. J., Carter, R. E., Yao, X., Rabinstein, A. A., Erickson, B. J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31721-0 · Cited by 1,613
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges
Chen, A., Stecker, E., & A. Warden, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.017559 · Cited by 666
Patel, I. J., Rahim, S., Davidson, J. C., Hanks, S. E., Tam, A. L., Walker, T. G., Wilkins, L. R., Sarode, R., & Weinberg, I. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2019.04.017 · Cited by 610
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeac106 · Cited by 507
Self-citation
Metadata
- Authors
- Lip, G. Y. H., Banerjee, A., Boriani, G., Chiang, C. E., Fargo, R., Freedman, B., Lane, D. A., Ruff, C. T., Turakhia, M., Werring, D., Patel, S., & Moores, L.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 154
- Issue
- 5
- Pages
- 1121-1201
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2888082174
- Cited by
- 939
- References
- 567
- FWCI
- 86.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.